Teachers Retirement System of The State of Kentucky Has $1.44 Million Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Teachers Retirement System of The State of Kentucky cut its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 6.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 17,674 shares of the medical equipment provider’s stock after selling 1,258 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in Hologic were worth $1,440,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in HOLX. Prentiss Smith & Co. Inc. raised its holdings in Hologic by 0.3% during the 3rd quarter. Prentiss Smith & Co. Inc. now owns 48,696 shares of the medical equipment provider’s stock worth $3,967,000 after purchasing an additional 130 shares during the last quarter. Covestor Ltd raised its stake in Hologic by 23.8% during the third quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock worth $56,000 after buying an additional 133 shares during the last quarter. First Horizon Advisors Inc. lifted its holdings in Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 134 shares during the period. Empirical Finance LLC boosted its position in Hologic by 1.8% during the third quarter. Empirical Finance LLC now owns 8,473 shares of the medical equipment provider’s stock valued at $690,000 after acquiring an additional 147 shares during the last quarter. Finally, Wedmont Private Capital grew its holdings in Hologic by 3.7% during the 3rd quarter. Wedmont Private Capital now owns 4,519 shares of the medical equipment provider’s stock worth $361,000 after acquiring an additional 162 shares during the period. 94.73% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages recently commented on HOLX. UBS Group upped their target price on Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Raymond James increased their price target on Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a report on Tuesday, November 5th. Mizuho lowered their price objective on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research note on Tuesday, November 5th. Needham & Company LLC reissued a “buy” rating and set a $90.00 target price on shares of Hologic in a research note on Tuesday, December 10th. Finally, Wolfe Research began coverage on shares of Hologic in a research note on Friday, December 13th. They issued a “peer perform” rating for the company. Six analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $89.50.

Hologic Trading Down 0.2 %

HOLX opened at $72.26 on Wednesday. Hologic, Inc. has a fifty-two week low of $70.24 and a fifty-two week high of $84.67. The firm has a market capitalization of $16.40 billion, a PE ratio of 21.70, a P/E/G ratio of 2.38 and a beta of 0.96. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. The company’s 50-day moving average is $79.01 and its 200 day moving average is $78.62.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, hitting the consensus estimate of $1.01. The firm had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The company’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.89 earnings per share. As a group, research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Insider Buying and Selling at Hologic

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the sale, the chief operating officer now owns 27,957 shares in the company, valued at approximately $2,134,237.38. This trade represents a 47.06 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 1.75% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.